R. Scott

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

S. Melquist, J. Knowles, P. Clifton, 2020 .

A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.

B. Neuschwander‐Tetri, K. Cusi, M. Yuen, 2022, Journal of hepatology.

Reduced Expression of Angiopoietin-Like Protein 3 via RNA Interference with ARO-ANG3 Produces Prolonged Reductions in LDL-C and Triglycerides in Dyslipidemic Patients

S. Melquist, J. Knowles, D. Gaudet, 2020 .